Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label teverelix loading-dose study in advanced prostate cancer
2005-005742-39Phase 2Completed
- Sponsor
- Ardana
- Start
- Dec 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teverelix in prostate cancer (PCa), sponsored by Ardana. Primary endpoint: Suppression of testosterone to castrate level. Started Dec 2005; status: completed.
02
Drugs
teverelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-005742-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005742-39.